Media Hub

Feb 2020

New gene therapy to halt rare inherited eye disorder

It is hoped that the new treatment, Luxturna, which costs around £600,000 and has been approved by the National Institute for Health and Care Excellence, will improve vision and even halt sight loss. The gene therapy will benefit patients who have retinal dystrophy, a condition which stems from inheriting a faulty copy of the RPE65…

Read More